---

$4.28

+0.0750 ( +1.79% ) 1.9M

OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3K¿H1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3K¿H1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K¿ and has multiple programs designed to enable targeting of this key oncogene.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-05-19	Buy	270270.00	ACORN BIOVENTURES, L.P.